dr. (Margreet) M.G. Franken

(external) researcher Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Location: Burg. Oudlaan 50, Rotterdam
Room: J 8-23
Telephone: +31 10 4081372
Email: franken@eshpm.eur.nl

Profile

Margreet Franken, PhD is a senior researcher at the institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands. She obtained a Bachelor degree in Nursing (1992), after which she specialised in coronary (1995) and intensive care nursing (1998). From 1992 until 2008 she worked as a quality care manager, clinical nurse educator, and specialised coronary and intensive care nurse in hospitals in Arnhem, Rotterdam and Christchurch (New Zealand). In 2008, Margreet obtained a masters degree (cum laude) in Health Economics, Policy and Law from the Erasmus University in Rotterdam. Since this time she has been working as a researcher at the institute for Medical Technology Assessment of the institute of Health Policy and Management at the Erasmus University in Rotterdam. In 2014, Margreet obtained her PhD on drug reimbursement decision making. She has been involved in setting up several patient registries in oncology. Her research interests are in the field of health economics and include drug reimbursement policies and outcomes research using real-world data. She is currently involved in disease registries for melanoma, multiple myeloma, colon and lung cancer.

- H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
- M.G. Franken, E. Heintz, A. Gerber-Grote & J. Raftery (2016). Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. Value in Health, 19 (8), 951-956. doi: 10.1016/j.jval.2016.08.001
- M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016
- M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: 10.1016/j.jval.2013.12.009
- M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
- M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: 10.1007/s40273-013-0074-1
- M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: 10.1016/j.ejca.2012.06.010
- - H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
  - M.G. Franken, E. Heintz, A. Gerber-Grote & J. Raftery (2016). Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. Value in Health, 19 (8), 951-956. doi: 10.1016/j.jval.2016.08.001
  - M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016
  - M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: 10.1016/j.jval.2013.12.009
  - M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
  - M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: 10.1007/s40273-013-0074-1
  - M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: 10.1016/j.ejca.2012.06.010
- - - H.M. Blommestein, C.H.Y. van Beurden-Tan, M.G. Franken, C.A. de Uyl-de Groot, P. Sonneveld & S. Zweegman (2019). Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A network meta-analysis. Haematologica. doi: 10.3324/haematol.2018.206912
    - M.G. Schouwenburg, A. Jochems, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, M.C.T. van Zeijl, M. Aarts, A.C.J. Akkooi, F. van den Berkmortel, W.A.M. Blokx, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, G. Vreugdenhil, M. Wouters & J.J.M. van der Hoeven (2018). Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 28 (4), 326-332. doi: 10.1097/cmr.0000000000000453
    - M.G. Franken, B. Leeneman, A. Jochems, M.G. Schouwenburg, M. Aarts, A.C.J. Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, J. de Groot, J.J.M. van der Hoeven, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters, M. Zeijl, J. Haanen & C.A. Uyl - de Groot (2018). Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 579-588. doi: 10.1097/CAD.0000000000000628
    - A. Jochems, B. Leeneman, M.G. Franken, M.G. Schouwenburg, M. Aarts, A.C.J. van Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, G. Groenewegen, J. de Groot, J. Haanen, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters, C.A. Uyl - de Groot & J.J.M. van der Hoeven (2018). Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 572-578. doi: 10.1097/CAD.0000000000000629
    - M.G. Franken, T.A. Kanters, J.L. Coenen, P. De Jong, H.R. Koene, P.J. Lugtenburg, A. Jager & C.A. de Uyl-de Groot (2018). Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anti-Cancer Drugs, 29 (8), 791-801. doi: 10.1097/CAD.0000000000000648
    - M.G. Franken, I. Corro Ramos, J. Los & M.J. Al (2018). The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 19 (31). doi: 1186/s12875-018-0714-9 [go to publisher's site]
    - A. Jochems, M.G. Schouwenburg, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, H. Gelderblom, C.A. de Uyl-de Groot, M. Aarts, F. van den Berkmortel, W.A.M. Blokx, M.C. Cardous-Ubbink, G. Groenewegen, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters & J.J.M. van der Hoeven (2017). Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 72, 156-165. doi: 10.1016/j.ejca.2016.11.021
    - C.H.Y. van Beurden-Tan, M.G. Franken, H.M. Blommestein, C.A. de Uyl-de Groot & P. Sonneveld (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35 (25), 2976. doi: 10.1200/JCO.2017.73.7569
    - H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
    - S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007
    - M.G. Franken, E. Heintz, A. Gerber-Grote & J. Raftery (2016). Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. Value in Health, 19 (8), 951-956. doi: 10.1016/j.jval.2016.08.001
    - M.G. Franken, E.A. Stolk, T. Scharringhausen, A. de Boer & M.A. Koopmanschap (2015). A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy, 119 (2), 195-202. doi: 10.1016/j.healthpol.2014.10.007
    - J.G. Gaultney, M.G. Franken, C.A. de Uyl-de Groot, W.K. Redekop, P.C. Huijgens, B. van der Holt, H.M. Lokhorst & P. Sonneveld (2015). Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. Health Policy, 119 (2), 186-194. doi: 10.1016/j.healthpol.2014.11.010
    - H.M. Blommestein, M.G. Franken & C.A. de Uyl-de Groot (2015). A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. Pharmacoeconomics (Print). doi: 10.1007/s40273-015-0260-4
    - M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016
    - M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: 10.1016/j.jval.2013.12.009
    - H.M. Blommestein, M.G. Franken, S.G.R. Verelst, M. van Agthoven, P.C. Huijgens & C.A. de Uyl-de Groot (2014). Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? Netherlands Journal of Medicine, 72 (4), 235-241. [go to publisher's site]
    - M.G. Franken & X.H.E. Koolman (2013). Health system goals: A discrete choice experiment to obtain societal valuations. Health Policy, 112 (1-2), 28-34. doi: 10.1016/j.healthpol.2012.12.013
    - F.G. Sandmann, M.G. Franken & A. Steenhoek (2013). Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy, 112 (3), 285-296. doi: 10.1016/j.healthpol.2013.03.006
    - M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: 10.1007/s40273-013-0074-1
    - M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: 10.1016/j.ejca.2012.06.010
    - J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2013). Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics, 38, 41-47. doi: 10.1111/jcpt.12020
    - M.G. Franken, M. le Polain, I. Cleemput & M.A. Koopmanschap (2012). SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS. International Journal of Technology Assessment in Health Care, 28 (4), 349-357. doi: 10.1017/S0266462312000530
    - J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2012). Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics. doi: 10.1111/jcpt.12020
    - I. Cleemput, M.G. Franken, M.A. Koopmanschap & M. le Polain (2012). EUROPEAN DRUG REIMBURSEMENT SYSTEMS' LEGITIMACY: FIVE-COUNTRY COMPARISON AND POLICY TOOL. International Journal of Technology Assessment in Health Care, 28 (4), 358-366. doi: 10.1017/S0266462312000529
    - S.S. Tan, C.W.M. van Gils, M.G. Franken, L. Hakkaart-van Roijen & C.A. de Uyl-de Groot (2010). The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology. Value in Health, 13 (6), 712-719. doi: 10.1111/j.1524-4733.2010.00740.x
  - - M.A. Koopmanschap, J.L. Severens & M.G. Franken (2012). Internationale aspecten bij besluitvorming inzake geneesmiddelenvergoeding. Economisch-Statistische Berichten, 97 (4644S), 36-39.
    - A. Steenhoek, M.A. Koopmanschap, M.G. Franken & F.F.H. Rutten (2010). Nieuwe geneesmiddelen: niet goed, geld terug? Nederlands Tijdschrift voor Geneeskunde, 154 (A2042), 1-5.
- - - M. le Polain, M.G. Franken, M.A. Koopmanschap & I. Cleemput (2010). Drug reimbursement systems: international comparison and policy recommendations. (Extern rapport, KCE Reports, no 147C). Brussel: Federaal Kenniscentrum voor de gezondheidszorg - Centre fédéral d'expertise des soins de santé
  - - M.G. Franken, J.G. Gaultney, H.M. Blommestein, S.S. Tan, C.W.M. van Gils, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2012). Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam - GE-iMTA [go to publisher's site]
- - M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
De Nederlandse Gezondheidszorg
Title
De Nederlandse Gezondheidszorg
Year
2018
Year level
(bachelor 1)
De Nederlandse Gezondheidszorg
Title
De Nederlandse Gezondheidszorg
Year
2018
Year level
(bachelor 1)
Ziekte en Gezondheid
Title
Ziekte en Gezondheid
Year
2018
Year level
(bachelor 1)
Ziekte en Gezondheid
Title
Ziekte en Gezondheid
Year
2018
Year level
(bachelor 1)
Management van Zorgorganisaties
Title
Management van Zorgorganisaties
Year
2018
Year level
(bachelor 1)
Management van Zorgorganisaties
Title
Management van Zorgorganisaties
Year
2018
Year level
(bachelor 1)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Year level
(bachelor 1)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Year level
(bachelor 1)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Year level
(bachelor 1)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Kwaliteit & Doelmatigheid
Title
Kwaliteit & Doelmatigheid
Year
2018
Year level
(bachelor 2)
Bachelorscriptie
Title
Bachelorscriptie
Year
2018
Year level
(bachelor 3)
(external) researcher
University
Erasmus University Rotterdam
School
Erasmus School of Health Policy & Management
Department
Health Technology Assessment (HTA)
Country
Nederland
Telephone
+31 10 4081372

Address

Visiting address

Burg. Oudlaan 50 3062 PA Rotterdam

Postal address

Postbus 1738 3000 DR Rotterdam

dr. (Margreet) M.G. Franken

More information

Profile

Featured publications (7)

All publications (38)

Key publication (7)

Article (28)

Scholarly Publication (26)

Professional Publication (2)

Report (2)

Scholarly Publication (1)

Other Publication (1)

Doctoral thesis (1)

Teaching (12)

Present position

(external) researcher

Address

Visiting address

Postal address